COX-2 elevates oncogenic miR-526b in breast cancer by EP4 activation

Molecular Cancer Research

Volumn 13, Issue 6, 2015, Pages 1022-1033

  Majumder, Mousumi ^a   Landman, Erin ^a   Liu, Ling ^a   Hess, David ^a   Lala, Peeyush K ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; MESSENGER RNA; MICRORNA; MICRORNA 526B; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ONO AE 3 208; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROTEIN KINASE B; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIRN526 MICRORNA, HUMAN; PROSTAGLANDIN E RECEPTOR; PROTEIN KINASE INHIBITOR; PTGER4 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MCF 7 CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BREAST TUMOR; CELL MOTION; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MICRORNAS; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84942316786     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0543     Document Type: Article

References (54)

1. Denkert C, Winzer K, Muller B, Weichert W, Pest S, KöbelM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-87.
2. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
3. Perrone G, Santini D, Verzi A, Borzomati D, Vecchio F, Coppola R, et al. COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. J Clin Pathol 2006;59:492-6.
4. Bhattacharjee R, Timoshenko A, Cai J, Lala PK. Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factorCup-regulation and lymphangiogenesis in human breast cancer. Cancer Sci 2010;101:2026-32.
5. Costa C, Soares R, Reis-Filho J, Amendoeira I, Schmitt F. Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Path 2002;55:429-34.
6. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-7.
7. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-90.
8. FujinoH, XuW, Regan J. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003;278:12151-6.
9. Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and betacatenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol 2009;23:1291-305.
10. Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 2013;65:1010-52.
11. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-711.
12. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006;296:1653-66.
13. Guo Y, Tukaye DN, Wu WJ, Zhu X, Book M, Tan W, et al. The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning. PLoS ONE 2012;7:e41178.
14. Lala PK, Parhar RS, Singh P. Indomethacin-therapy abrogates in prostaglandinmediated suppression of natural killer activity in tumor bearing mice and prevents tumor metastasis. Cell Immunol 1986;99:108-18.
15. Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take A, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Onco Immunology 2013;2:1-8.
16. Rozic J, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness, and angiogenesis. Int J Cancer 2001;93:497-506.
17. Xin X, MajumderM, GirishG, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis, and metastasis to the lungs and lymph nodes in a breast cancer. Lab Invest 2012;92:1115-28.
18. Timoshenko A, Chakraborty C, Wagner G, Lala PK. COX-2-mediated upregulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006;94:1154-63.
19. Majumder M, Xin X, Liu L, Lala PK. EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymph-angiogenesis, metastasis and SLC functions. Cancer Sci 2014;105:1142-51.
20. Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat 2014;143:19-31.
21. Chell S, Witherden I, Dobson R, Moorghen M, Herman AA, Qualtrough D, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006;66:3106-13.
22. Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
23. Andorfer C, Necela B, Thompson E, Perez E. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Cell 2011;17:313-9.
24. Lu J, Getz G, Miska E, Alvarez E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
25. van'T Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
26. Dumont N, Tlsty T. Reflections on miR-ing effects in metastasis. Cancer Cell 2009;16:3-4.
27. Shi M, Liu D, Duan H, Shen B, Guo N. Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 2010;29:785-99.
28. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010;11:252-63.
29. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9.
30. Ward A, Balwierz A, Zhang J, Küblbeck M, Pawitan Y, Hielscher T, et al. Reexpression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013;32:1173-82.
31. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, et al. microRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013;62:1315-26.
32. Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson DA, et al. Argonaute 2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. PNAS 2011;108:5003-8.
33. Sleeman J, Cremers N. New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clin Exp Metastasis 2007;24:707-15.
34. WichaM, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006;66:1883-90.
35. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23.
36. Shimono Y, Zabala M, Cho R, Lobo N, Dalerba P, Qian D, et al. Downregulation ofmiRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138:592-603.
37. Summerton J. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 2007;7:651-60.
38. Timoshenko A, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289:265-74.
39. Dontu G, Abdallah W, Foley J, Jackson K, Clarke M, KawamuraMJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70.
40. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
41. Blenkiron C, Miska EA. miRNAs in cancer: approaches, aetiology, diagnostics, and therapy. Hum Mol Genet 2007;1:R106-13.
42. Zadran S, Remacle F, Levine RD. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci U S A 2013;110:19160-5.
43. Heneghan H, Miller N, Kelly R, Newell J, Kerin M. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting non-invasive and early stage disease. Oncologist 2010;15:673-82.
44. Riaz M, van Jaarsveld MT, Hollestelle A, Prager-van der Smissen WJ, Heine AA, Boersma AW, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Research 2013;15:R33.
45. Heneghan H, Miller N, Lowery A, Sweeney K, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010;251:499-505.
46. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 2010;5:e13735.
47. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013;132:1602-12.
48. Aigner A. MicroRNA (miRNA) in cancer invasion and metastasis: therapeutic approaches based on metastasis related miRNAs. J Mol Med 2011;89:445-57.
49. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, et al. The miR-106b-25 cluster targets Smad7, activates TGF-b signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012;31:5162-71.
50. Ma L, Teruya-Feldstein J, Weinberg R. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-9.
51. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNAgene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
52. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, aMYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12:247-56.
53. Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat 2014 147:39-49.
54. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005;446:475-82.